Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules
Biomarker Research · 21.03.2024 · 12 (1)
DOI: 10.1186/s40364-024-00580-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomarker Research, online erschienen am 21.03.2024. Verfasst von Ali Hazrati und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 291 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mesenchymal stromal/stem cells (MSCs) are used in many studies due to their therapeutic potential, including their differentiative ability and immunomodulatory properties. These cells perform their therapeutic functions by using various mechanisms, such as the production of anti-inflammatory cytokines, growth factors, direct cell-to-cell contact, extracellular vesicles (EVs) production, and mitochondrial transfer. However, mechanisms related to immune checkpoints (ICPs) and their effect on the immunomodulatory ability of MSCs are less discussed. The main function of ICPs is to prevent the initiation of unwanted responses and to regulate the immune system responses to maintain the homeostasis of these responses. ICPs are produced by various types of immune system regulatory cells, and defects in their expression and function may be associated with excessive responses that can ultimately lead to autoimmunity. Also, by expressing different types of ICPs and their ligands (ICPLs), tumor cells prevent the formation and durability of immune responses, which leads to tumors' immune escape. ICPs and ICPLs can be produced by MSCs and affect immune cell responses both through their secretion into the microenvironment or direct cell-to-cell interaction. Pre-treatment of MSCs in inflammatory conditions leads to an increase in their therapeutic potential. In addition to the effect that inflammatory environments have on the production of anti-inflammatory cytokines by MSCs, they can increase the expression of various types of ICPLs. In this review, we discuss different types of ICPLs and ICPs expressed by MSCs and their effect on their immunomodulatory and therapeutic potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. samirarajaei@gmail.com.
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. smmhashemi@sbmu.ac.ir.
Zitieren
APA
Hazrati, A., Malekpour, K., Khorramdelazad, H., Rajaei, S., & Hashemi, S. M. (2024). Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules. Biomarker Research, 12(1). https://doi.org/10.1186/s40364-024-00580-2
Vancouver
Hazrati A, Malekpour K, Khorramdelazad H, Rajaei S, Hashemi SM. Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules. Biomarker Research. 2024;12(1). doi:10.1186/s40364-024-00580-2
BibTeX
@article{Hazrati2024,
author = {Hazrati, Ali and Malekpour, Kosar and Khorramdelazad, Hossein and Rajaei, Samira and Hashemi, Seyed Mahmoud},
title = {Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules},
journal = {Biomarker Research},
year = {2024},
volume = {12},
number = {1},
doi = {10.1186/s40364-024-00580-2}
}
EUVIMED